BioSpace News Archive

Sonoma Pharmaceuticals, Inc. and its partner, the MicroSafe Group DMCC, are pleased to announce that Nanocyn® hospital grade disinfectant has been added to the list of COVID-19 disinfectants maintained by the U.S. Environmental Protection Agency’s List N.

Dexcom, Inc. announced that people with type 1 and type 2 diabetes age two and over on multiple daily injections of insulin or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System through Prince Edward Island’s Diabetes Glucose Sensor Program.

OrthoTrophix, Inc. announced that the Company will present the latest clinical data and registration plan of TPX-100 in knee osteoarthritis patients at BIO 2022.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced that it has been added to the new 2022 Consensus Guidelines of the International Surgical Wound Complications Advisory Panel.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the first quarter ended March 31, 2022 and provided an update on clinical and corporate progress.

Design Therapeutics, Inc. announced that João Siffert, M.D., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 8:30 a.m. ET in New York City.

BIOLASE, Inc., the global leader in dental lasers, announced that due to the growing adoption of its market leading laser technology, BIOLASE has taken the innovative step of creating a multi-dimensional integration team to support the optimal use of BIOLASE dental lasers in practices across North America.

Bioretec Ltd ( HELSINKI : BRETEC) Forearm fractures are a common injury in children and adolescents.

Sage Therapeutics, Inc. and Biogen Inc. announced that the Phase 3 SKYLARK Study of zuranolone, an investigational oral drug being evaluated in women with postpartum depression, met its primary and all key secondary endpoints.

AmerisourceBergen Corporation reiterated its previously provided guidance for fiscal year 2022 and announced that its Board of Directors has authorized a new share repurchase program.